KRAS G12C-mutant colorectal cancer

What changed: KRAS G12C-mutant colorectal cancer

Cancer page →

Every dated change on the records linked to KRAS G12C-mutant colorectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval2Regulatory2Trial result3Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordKRAS G12C-mutant colorectal cancer
Facts on this page last checked
When this page itself was last checked or edited.

January 2025 · 1

2025-01-16RegulatorySotorasib
Sotorasib: approval (US)
KRAS G12C colorectal cancer with panitumumab (CodeBreaK 300)

2025 · 2

June 2024 · 1

2024-06-21RegulatoryAdagrasib
Adagrasib: approval (US)
KRAS G12C colorectal cancer with cetuximab (accelerated)

2024 · 2

2023 · 4

2021 · 1

2021MilestoneSotorasib
Sotorasib becomes the first approved KRAS inhibitor (lung cancer)
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneKRAS
Ostrem and Shokat describe covalent inhibitors of KRAS G12C
A milestone in how this cancer is treated.

2008 · 1

2008MilestoneCetuximab
KRAS mutations shown to predict failure of cetuximab and panitumumab
A milestone in how this cancer is treated.

1982 · 1

1982MilestoneKRAS
KRAS identified as a human oncogene
A milestone in how this cancer is treated.